Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026

globe_newswire · 2026-10-21

$IVVD

NEW HAVEN, Conn., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the presentation of preclinical data describing its novel, potential first- and best-in-class investigational monoclonal antibody candidate VMS063 at IDWeek 2026™ in Washington, D.C. Data demonstrated highly potent in vitro antiviral activity against contemporary measles fusion protein (MeV-F) variants, supporting its potential utility for both treatment and prevention (pre/post-exposure prophylaxis)

Sector coverage: Healthcare · Biotechnology

Read the original at globe_newswire ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.